<DOC>
	<DOCNO>NCT00131235</DOCNO>
	<brief_summary>The purpose study examine whether treatment pregnant Malawian woman repeat dos sulfadoxine-pyrimethamine azithromycin antibiotic prevent preterm delivery result health benefit mother foetus/newborn .</brief_summary>
	<brief_title>Gestational Sulfadoxine-pyrimethamine Azithromycin Treatment Prevent Preterm Birth</brief_title>
	<detailed_description>Maternal anaemia , preterm delivery low birth weight common Sub-Saharan Africa contribute significantly ill-health pregnant woman infant . The present study base assumption adverse outcomes prevent improve antimicrobial management malaria sexually transmit infection ( STI ) among pregnant woman . To test hypothesis , randomise clinical trial follow Good Clinical Practice ( GCP ) carry Malawi , South-Eastern Africa . A total 1320 consent woman present rural antenatal clinic 14 26 complete gestation week enrol . One third woman receive antenatal care accord national recommendation , include regular visit health centre , screen pregnancy complication , haematinic vitamin A supplementation two dos presumptive malaria treatment sulfadoxine-pyrimethamine . Another third receive otherwise care , sulfadoxine-pyrimethamine treatment give monthly interval . The final third receives standard antenatal care , sulfadoxine-pyrimethamine treatment monthly interval two dos presumptive STI treatment azithromycin . Women monitor throughout pregnancy delivery newborn growth follow five year . The primary outcome measure proportion preterm birth three study group . Secondary maternal outcome include anaemia malaria parasitaemia pregnancy , delivery 1 , 3 , 6 month delivery , gestational weight gain morbidity STI prevalence delivery . Secondary child outcome consist proportion baby low birth weight , mean birth weight , growth infancy childhood , incidence malnutrition infancy childhood , mortality . Additionally , information collect development malaria-specific humoral immunity pregnancy participant experience study . Participant safety systematically monitor throughout intervention .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Signed informed consent Age &gt; = 15 year Ultrasound confirm pregnancy Quickening Foetal age 1426 gestation week Maternal availability followup entire study period Known maternal tuberculosis , diabetes , kidney disease liver disease Any severe acute illness warrant hospital referral enrollment visit Mental disorder may affect comprehension study success followup Twin pregnancy Pregnancy complication evident enrollment visit ( moderate severe oedema , blood hemoglobin [ Hb ] concentration &lt; 50 g/l , systolic blood pressure [ BP ] &gt; 160 mmHg diastolic BP &gt; 100 mmHg ) Prior receipt azithromycin pregnancy Receipt sulfadoxine pyrimethamine within 28 day enrollment Known allergy drug contain sulfonamide , macrolides pyrimethamine History anaphylaxis History serious allergic reaction substance , require emergency medical care Concurrent participation clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Malaria</keyword>
	<keyword>STI</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Prevention</keyword>
	<keyword>Preterm birth</keyword>
	<keyword>Low birth weight</keyword>
	<keyword>Sub-Saharan Africa</keyword>
</DOC>